A practical reference on Immunomodulatory peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-04 and is reviewed periodically as new material appears.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
The couple are still involved in their grown children's lives, but their "empty nest" grows crowded when Darlene, now a single mother, moves back home with her two children after losing her publishing job in Chicago, creating new conflicts and stresses. In The Conners, Dan is now a widower, Roseanne having died from an accidental overdose of pain pills. He deeply mourns her death, but after two years begins dating Louise, a former high-school classmate. Dan also becomes a grandfather a fourth time after Becky gives birth to a daughter. Though Dan was the father of four in Roseanne, youngest son Jerry has been retconned out of existence, and there are only three Conner children. In Season 3, Dan realizes he is too old to continue working as a contractor and retires. He begins working at the hardware store owned by Darlene's boyfriend, Ben. In an article about television dads, The Post and Courier editor Mindy Spar discussed how '90s TV dads became goofier than dads from earlier decades, calling Dan more like one of the children than the father. IGN editor Edgar Arce called Dan Conner a prototypical everyman. An article in the Sarasota Herald-Tribune praised Dan and Roseanne's relationship, calling it realistic and commenting that while they mock each other, viewers can feel their love while they deal with the kinds of problems real families face. Daily News editor David Bianculli stated that while they were the most entertaining and realistic couple on television, they were one of the least during their separation.
=== Brand names === Cyclofenil has been marketed under a variety of brand names including Ciclifen, Fertodur, Gyneuro, Klofenil, Menoferil, Menopax, Neoclym, Oginex, Ondonid, Ondogyne, Rehibin, Sexadieno, Sexovar, and Sexovid.
=== Origin === Like all elements with atomic weights higher than that of iron, uranium is only naturally formed by the r-process (rapid neutron capture) in supernovae and neutron star mergers. Primordial thorium and uranium are only produced in the r-process, because the s-process (slow neutron capture) is too slow and cannot pass the gap of instability after bismuth. Besides the two extant primordial uranium isotopes, 235U and 238U, the r-process also produced significant quantities of 236U, which has a shorter half-life and so is an extinct radionuclide, having long since decayed completely to 232Th. Further uranium-236 was produced by the decay of 244Pu, accounting for the observed higher-than-expected abundance of thorium and lower-than-expected abundance of uranium. While the natural abundance of uranium has been supplemented by the decay of extinct 242Pu (half-life 375,000 years) and 247Cm (half-life 16 million years), producing 238U and 235U respectively, this occurred to an almost negligible extent due to the shorter half-lives of these parents and their lower production than 236U and 244Pu, the parents of thorium: the 247Cm/235U ratio at the formation of the Solar System was (7.0±1.6)×10−5.
== Amyloid beta regulation == Neprilysin-deficient knockout mice show both Alzheimer's-like behavioral impairment and amyloid-beta deposition in the brain, providing strong evidence for the protein's association with the Alzheimer's disease process. Because neprilysin is thought to be the rate-limiting step in amyloid beta degradation, it has been considered a potential therapeutic target; compounds such as the peptide hormone somatostatin have been identified that increase the enzyme's activity level. Declining neprilysin activity with increasing age may also be explained by oxidative damage, known to be a causative factor in Alzheimer's disease; higher levels of inappropriately oxidized neprilysin have been found in Alzheimer's patients compared to cognitively normal elderly people.
Sources: en.wikipedia.org
As a result of illegal tactics, including illegal surveillance and vigilantism, used by the RCMP Security Service and the consequent scandals surrounding the RCMP, intelligence work was transferred to a new agency, CSIS in 1984 through the implementation of Bill C-9.
== Honors and awards == American Heart Association Basic Research Prize (1993) William B. Coley Award for Distinguished Research in Basic and Tumor Immunology (1995) Member of the National Academy of Sciences (1996) Member of the National Academy of Medicine (2023) Fellow of the American Academy of Arts and Sciences (2001) Crafoord Prize in Polyarthritis (2004) Guggenheim Fellowship (2004) Fellow of the American Association for the Advancement of Science (2013) AAI-Life Technologies Meritorious Career Award (now AAI-Thermo Fisher Meritorious Career Award), American Association of Immunologists (2014) Henry M. Stratton Medal, American Society of Hematology (2014) Canada Gairdner International Award (2019) Albert Lasker Award for Basic Medical Research (2022) Robert Koch Prize (2023) Biophysical Society Founders Award (2022) The Protein Society Stein & Moore Award (2025) Fellow of the National Academy of Inventors (2025) Included in Forbes’ 250: America’s Greatest Innovators list (2026) Selected to receive the American Society for Biochemistry and Molecular Biology’s Bert and Natalie Vallee Award in Biomedical Science (2027) He was a Phi Beta Kappa graduate from the University of California, Berkeley.
Gearbox has developed a total of six games in the Half-Life series: the expansion packs Opposing Force and Blue Shift; ports of Half-Life for Dreamcast (which included Blue Shift) and Half-Life for PlayStation 2 (which included Half-Life: Decay); it also did a large amount of work on both the retail release of Counter-Strike and the main portion of Counter-Strike: Condition Zero.
Feminizing hormone therapy, also known as transfeminine hormone therapy, is a form of gender-affirming hormone therapy (GAHT) which change the primary and secondary sex characteristics of transgender people from masculine to feminine. It is one of the two common type of GAHT the other being masculinizing hormone therapy) and is used to treat transgender women and non-binary transfeminine individuals. Some others, in particular intersex people, but also some non-transgender people, take this form of therapy according to their personal needs and preferences. The purpose of the therapy is to cause the development of the secondary sex characteristics of the desired sex, such as breasts and a feminine pattern of hair, fat, and muscle distribution. It cannot undo many of the changes produced by naturally occurring puberty, which may necessitate surgery and other treatments to reverse (see below). The medications used for feminizing hormone therapy include estrogens, antiandrogens, progestogens, and gonadotropin-releasing hormone modulators (GnRH modulators). Feminizing hormone therapy has been empirically shown to reduce the distress and discomfort associated with gender dysphoria in transfeminine individuals.
=== Life expectancy === The life expectancy in Bromley Town ward (which covers the town centre) was 79.3 years for males and 83.7 years for females, during 2009–2013. The highest in the town were in Shortlands: 86.1 years for males and 88.1 years for females. The lowest for both genders was in Plaistow and Sundridge: 77.5 and 82.1 years respectively.
Sources: en.wikipedia.org
Throughout recorded history, attempts at producing a state of general anesthesia can be traced back to the writings of ancient Sumerians, Babylonians, Assyrians, Akkadians, Egyptians, Persians, Indians, and Chinese. Despite significant advances in anatomy and surgical techniques during the Renaissance, surgery remained a last-resort treatment largely due to the pain associated with it. This limited surgical procedures to addressing only life-threatening conditions, with techniques focused on speed to limit blood loss. All of these interventions carried high risk of complications, especially death. Around 80% of surgeries led to severe infections, and 50% of patients died either during surgery or from complications thereafter. Many of the patients who were fortunate enough to survive remained psychologically traumatized for the rest of their lives. However, scientific discoveries in the late 18th and early 19th centuries paved the way for the development of modern anesthetic techniques. The 19th century was filled with scientific advancements in pharmacology and physiology. During the 1840s, the introduction of diethyl ether (1842), nitrous oxide (1844), and chloroform (1847) as general anesthetics revolutionized modern medicine. The late 19th century also saw major advancements to modern surgery with the development and application of antiseptic techniques as a result of the germ theory of disease, which significantly reduced morbidity and mortality rates.
== Function == G protein-coupled receptors (GPCRs, or GPRs) contain 7 transmembrane domains and transduce extracellular signals through heterotrimeric G proteins. A 26-amino acid RF-amide peptide, P518 functions as a high-affinity ligand of GPR103. Both GPR103 and P518 precursor mRNA exhibited highest expression in brain. The 43-amino acid QRFP peptide, a longer form of the P518 peptide is necessary to exhibit full agonistic activity with GPR103. Intravenous administration QRFP caused release of aldosterone, suggesting that QRFP and GPR103 regulate adrenal function.
== Rheumatism, excluding the back (725–729) == 725 Polymyalgia rheumatica 726 Peripheral enthesopathies and allied syndromes 726.0 Adhesive capsulitis, shoulder 726.1 Rotator cuff syndrome, NOS (Not Otherwise Specified) 726.12 Bicipital tenosynovitis 726.3 Enthesopathy of elbow region 726.31 Medial epicondylitis 726.32 Lateral epicondylitis 726.33 Olecranon bursitis 726.4 Enthesopathy of wrist and carpus 726.5 Enthesopathy of hip region 726.6 Enthesopathy of knee 726.61 Pes anserinus tendinitis 726.64 Tendinitis, patellar 726.65 Prepatellar bursitis 726.7 Metatarsalgia, NOS (Not Otherwise Specified) 726.71 Tendinitis, achilles 726.72 Tendinitis, tibialis 726.73 Calcaneal spur 727 Other disorders of synovium, tendon and bursa 727.0 Synovitis and tenosynovitis 727.00 Synovitis/tenosynovitis, unspec. 727.03 Trigger finger, acquired 727.04 de Quervain's disease 727.05 Tenosynovitis, hand/wrist 727.06 Tenosynovitis, foot/ankle 727.1 Bunion 727.4 Ganglion and cyst of synovium, tendon, and bursa 727.42 Ganglion, tendon sheath 727.43 Ganglion, unspec.
=== Other factors === Not getting enough sleep is also associated with obesity. Whether one causes the other is unclear. Even if short sleep does increase weight gain, it is unclear if this is to a meaningful degree or if increasing sleep would be of benefit. Some researchers have proposed that chemical compounds called "obesogens" (a category that includes certain endocrine-disrupting chemicals such as bisphenols and phthalates) may play a role in obesity. Certain aspects of personality are associated with being obese. Loneliness, neuroticism, impulsivity, and sensitivity to reward are more common in people who are obese while conscientiousness and self-control are less common in people who are obese. Because most of the studies on this topic are questionnaire-based, it is possible that these findings overestimate the relationships between personality and obesity: people who are obese might be aware of the social stigma of obesity and their questionnaire responses might be biased accordingly. Similarly, the personalities of people who are obese as children might be influenced by obesity stigma, rather than these personality factors acting as risk factors for obesity. In relation to globalization, it is known that trade liberalization is linked to obesity; research, based on data from 175 countries during 1975–2016, showed that obesity prevalence was positively correlated with trade openness, and the correlation was stronger in developing countries.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.